These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27295141)

  • 1. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
    ElNaggar AC; Hays JL; Chen JL
    PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
    Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
    Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
    Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
    Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
    Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
    Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for maintenance therapy in managing sarcoma.
    Ray-Coquard I; Le Cesne A
    Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.
    Reichardt P; Pink D; Tilgner J; Kretzschmar A; Thuss-Patience PC; Dörken B
    Onkologie; 2002 Dec; 25(6):541-6. PubMed ID: 12566899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
    Mita MM; Gong J; Chawla SP
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
    Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
    J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mTOR inhibitors for treatment of sarcomas.
    Mita MM; Tolcher AW
    Curr Oncol Rep; 2007 Jul; 9(4):316-22. PubMed ID: 17588357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
    Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.